Connect with us

Hi, what are you looking for?

Economy

Trump nominees debut new science journal aimed at spurring scientific discourse, increasing transparency

President Donald Trump’s nominees to run the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) are part of a group of scientists who just launched a new research journal focused on spurring scientific discourse and combating ‘gatekeeping’ in the medical research community. 

The journal, titled the Journal of the Academy of Public Health (JAPH), includes an editorial board consisting of several scientists who complained of facing censorship during the COVID-19 pandemic.

JAPH’s co-founders include Martin Kulldorff, a former Harvard Medical School professor who is a founding fellow at Hillsdale College’s Academy for Science and Freedom, and Dr. Jay Bhattacharya, a professor of health policy at Stanford University who is also Trump’s nominee to be the next NIH director. Kulldorff and Bhattacharya became known during the pandemic for authoring The Great Barrington Declaration, which sought to challenge the broader medical community’s prevailing notions about COVID-19 mitigation strategies, arguing that – in the long run – the lockdowns that people were facing would do more harm than good.

Dr. Marty Makary, a surgeon and public policy researcher at Johns Hopkins University, who is Trump’s nominee to be the next director of the FDA, is on the journal’s editorial board as well.  

JAPH is adopting a novel approach by publishing peer reviews of prominent studies from other journals that do not make their peer reviews publicly available. The effort is aimed at spurring scientific discourse, Kulldorff said in a paper outlining the purposes of the journal’s creation.

The journal will also seek to promote ‘open access’ by making all of its work available to everyone in the public without a paywall, he said, and the journal’s editorial leadership will allow all scientists within its network to ‘freely publish all their research results in a timely and efficient manner,’ to prevent any potential ‘gatekeeping.’

‘Scientific journals have had enormous positive impact on the development of science, but in some ways, they are now hampering rather than enhancing open scientific discourse,’ Kulldorff said. ‘After reviewing the history and current problems with journals, a new academic publishing model is proposed – it embraces open access and open rigorous peer review, it rewards reviewers for their important work with honoraria and public acknowledgment and it allows scientists to publish their research in a timely and efficient manner without wasting valuable scientist time and resources.’

Kulldorff, Bhattacharya, Makary and others on the new journal’s leadership team have complained that their views about the COVID-19 pandemic were censored. These were views that were often contrary to the prevailing ideas put forth by the broader medical community at the time, which related to topics such as vaccine efficacy, natural immunity, lockdowns and more.

‘Big tech censored the [sic] all kinds of science on natural immunity,’ Makary said in testimony to Congress following the pandemic. During his testimony, Makary also shared how one of his own studies at Johns Hopkins during the pandemic that promoted the effectiveness of natural immunity, which one scientific journal listed as its third most discussed study in 2022, ‘was censored.’

‘Because of my views on COVID-19 restrictions, I have been specifically targeted for censorship by federal government officials,’ Bhattacharya added in his own testimony to Congress the same year.

Kulldorff, who has also complained about censorship of his views on COVID-19, argued he was asked to leave his medical professorship at Harvard that he held since 2003, for ‘clinging to the truth’ in his opposition to COVID-19 lockdowns and vaccine mandates.

‘The JAPH will ensure quality through open peer-review, but will not gatekeep new and important ideas for the sake of established orthodoxies,’ Andrew Noymer, JAPH’s incoming editor-in-chief told Fox News Digital. 

‘To pick one example, in my own sub-field of infectious disease epidemiology, we have in the past few years seen too little published scholarship on the origins of SARS-CoV-2, the virus that causes COVID. Academic publishing as it exists today is too often concerned with preservation of what we think we know, too often to the detriment of new ideas.’

Bhattacharya and Makary did not wish to comment on this article.

This post appeared first on FOX NEWS

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.






    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Latest News

    Kim Jong Un attended a “paramilitary parade” with his daughter to mark the 75th anniversary of North Korea’s founding on Saturday, the country’s state...

    Stock

    Target said Tuesday that it will close nine stores in major cities across the country, citing violence, theft and organized retail crime. The company will...

    Investing

    Cybercrimes are a growing problem for individuals, businesses and governments alike. Still, many people continue to ask the question, “Why is cybersecurity important?” For...

    Economy

    Israel plans to partially withdraw its forces from Gaza in the coming months as the war against Hamas enters a new phase Monday. Israeli...

    Disclaimer: aimyourdeals.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2023 aimyourdeals.com